Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief

Karabajakian, Andy; Gau, Max; Reverdy, Thibaut; Neidhardt, Ève-Marie; Fayette, Jérôme

doi:10.3390/cancers11010015

Cited by 20 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 27 ] Other possible reasons for stable burden interference in this study may be the advancement in medical treatment, such as more medications to prevent or alleviate side effects of cancer treatment. [ 26 28 ] Moreover, 88.9% of this study participants were male, they might under-report symptom interference although they did experience severe symptom burden. This may be due to the gender stereotype of men in Asian culture that is taking charge and being in control.…”

Section: Discussionmentioning

confidence: 95%

Predictors of Quality of Life Change in Head-and-Neck Cancer Survivors during Concurrent Chemoradiotherapy: A Prospective Study

Tsan

Wung

Lin³

et al. 2021

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Objective: Head-and-neck cancer (HNC) and its treatment impact patients' quality of life (QoL) and survival. The symptom burden of HNC survivors severely affects QoL, while hope serves as an impetus for adjustment that enables survivors to sustain basic QoL. This study investigated the change of QoL, symptom burden, and hope and the predictors of QoL change in HNC survivors from diagnosis to 3 months after concurrent chemoradiotherapy (CCRT) completing. Methods: This was a prospective, correlational study conducted between January 2016 and April 2017 at a medical center in northern Taiwan. Purposive sampling 54 adults newly diagnosed with HNC had completed the first CCRT. The questionnaires of Functional Assessment of Cancer Therapy-HNC Scale, M. D. Anderson Symptom Inventory, and Herth Hope Index were collected. The five measuring times were before CCRT (T1), the 3 rd –4 th week of CCRT (T2), the last week of CCRT (T3), and 1 month (T4) and 3 months (T5) after the completion of CCRT. Results: The change of QoL first declined and then rose at T2–T5. The change of symptom burden increased initially and then declined at T2–T5. The change of hope remained steady between T1 and T5. The change of symptom burden and hope significantly predicted the change of QOL over time. Conclusions: Clinicians are suggested to assess symptom burden and hope regularly in HNC during their CCRT and, if needed, promptly provide interprofessional care in time. Reducing symptom burden and maintaining a mindful hope could improve QoL in HNC survivors during CCRT.

show abstract

Section: Discussionmentioning

confidence: 95%

Predictors of Quality of Life Change in Head-and-Neck Cancer Survivors during Concurrent Chemoradiotherapy: A Prospective Study

Tsan

Wung

Lin³

et al. 2021

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

show abstract

“…The main factor limiting both the dose and the number of cycles in iCHT is treatment-induced toxicity. TPF schedule demonstrates a better response rate than PF, but due to its less favorable toxicity profile, a PF arm is preferred in the patients with poorer performance status or burdened with a severe comorbidity and in age >70 years ( 58 , 59 ). Standard iCHT protocols involve the administration of 3 to 4 cycles ( 2 , 59 ), however, it has been recently shown that two cycles of iCHT might be sufficient in case of nasopharyngeal cancer and additional more cycles did not lead to survival benefit ( 60 ).…”

Section: Resultsmentioning

confidence: 99%

“…TPF schedule demonstrates a better response rate than PF, but due to its less favorable toxicity profile, a PF arm is preferred in the patients with poorer performance status or burdened with a severe comorbidity and in age >70 years ( 58 , 59 ). Standard iCHT protocols involve the administration of 3 to 4 cycles ( 2 , 59 ), however, it has been recently shown that two cycles of iCHT might be sufficient in case of nasopharyngeal cancer and additional more cycles did not lead to survival benefit ( 60 ). The adverse iCHT effects may appear even after the first cycle, having a significant negative impact on the patient’s ability to undergo therapy ( 61 ).…”

Section: Resultsmentioning

confidence: 99%

Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers

Boguszewicz

2022

Front. Oncol.

View full text Add to dashboard Cite

This review focuses on the molecular biology of head and neck squamous cell carcinomas and presents current and emerging biomarkers of the response of patients to induction chemotherapy. The usefulness of genes, proteins, and parameters from diagnostic clinical imaging as well as other clinicopathological parameters is thoroughly discussed. The role of induction chemotherapy before radiotherapy or before chemo-radiotherapy is still debated, as the data on its efficacy are somehow confusing. Despite the constant improvement of treatment protocols and the introduction of new cytostatics, there is still no consensus regarding the use of induction chemotherapy in the treatment of head and neck cancer, with the possible exception of larynx preservation. Such difficulties indicate that potential future treatment strategies should be personalized. Personalized medicine, in which individual tumor genetics drive the selection of targeted therapies and treatment plans for each patient, has recently emerged as the next generation of cancer therapy. Early prediction of treatment outcome or its toxicity may be highly beneficial for those who are at risk of the development of severe toxicities or treatment failure—a different treatment strategy may be applied to these patients, sparing them unnecessary pain. The literature search was carried out in the PubMed and ScienceDirect databases as well as in the selected conference proceedings repositories. Of the 265 articles and abstracts found, only 30 met the following inclusion criteria: human studies, analyzing prediction of induction chemotherapy outcome or toxicity based on the pretreatment (or after the first cycle, if more cycles of induction were administered) data, published after the year 2015. The studies regarding metastatic and recurrent cancers as well as the prognosis of overall survival or the outcome of consecutive treatment were not taken into consideration. As revealed from the systematic inspection of the papers, there are over 100 independent parameters analyzed for their suitability as prognostic markers in HNSCC patients undergoing induction chemotherapy. Some of them are promising, but usually they lack important features such as high specificity and sensitivity, low cost, high positive predictive value, clinical relevance, short turnaround time, etc. Subsequent studies are necessary to confirm the usability of the biomarkers for personal medicine.

show abstract

“…International Publisher commonly used in chemotherapy [11,12]. Nevertheless, about 70-80% recurrent OSCC patients are resistant to cisplatin and their clinical outcomes are largely restricted by drug resistance [13,14].…”

Section: Ivyspringmentioning

confidence: 99%

Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell carcinoma

An¹,

Chu²,

Yang³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

MicroRNAs are major post-transcriptional regulators responsible for the development of human cancers, including OSCC. The specific role of miR-619-5p in OSCC, however, is rarely reported. Cisplatin is one of the mostly applied chemotherapy drugs of OSCC. Nevertheless, drug resistance of cisplatin following the initial chemotherapy largely restricts its clinical benefits, and the mechanism of cisplatin resistance is unclear. This study intends to explore the biological function of miR-619-5p in the development of cisplatin resistance in OSCC cell lines and a xenograft model, as well as the potential molecular mechanism. Our results showed that miR-619-5p was down-regulated in OSCC samples and cisplatin-resistant OSCC cells. Ectopically expressed miR-619-5p inhibited proliferative, migratory and invasive abilities of OSCC cisplatin-resistant cells. The putative target gene ATXN3 was predicted by bioinformatic analysis and confirmed by dual-luciferase reporter assay. Importantly, ATXN3 was responsible for the regulatory effects of miR-619-5p on biological behaviors of cisplatin-resistant OSCC cells. Moreover, miR-619-5p mimics and ATXN3-siRNA significantly enhanced ATXN3 knockdown in both HN6/CDDPR and CAL27/CDDPR cells and inhibited expression of PI3K and AKT. In vivo evidences demonstrated that intratumoral injection of miR-619-5p agomir remarkably slowed down the growth of OSCC in xenograft mice. Collectively, microRNA-619-5p was the vital regulator for regulating cisplatin resistance of OSCC, which may be served as a potential therapeutic target.

show abstract

Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Question of Belief

Cited by 20 publications

References 40 publications

Predictors of Quality of Life Change in Head-and-Neck Cancer Survivors during Concurrent Chemoradiotherapy: A Prospective Study

Predictors of Quality of Life Change in Head-and-Neck Cancer Survivors during Concurrent Chemoradiotherapy: A Prospective Study

Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers

Involvement of miR-619-5p in resistance to cisplatin by regulating ATXN3 in oral squamous cell carcinoma

Contact Info

Product

Resources

About